NCT00002787 is a Phase 1 clinical trial of autologous immunoglobulin idiotype-KLH conjugate vaccine in Refractory Multiple Myeloma, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.

What drugs are being tested in NCT00002787?

Interventions in NCT00002787: autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, aldesleukin, laboratory biomarker analysis.

What condition does NCT00002787 study?

NCT00002787 studies Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma.

Is NCT00002787 still recruiting?

NCT00002787 is currently completed. Last updated 2 May 2019.

Last reviewed 2019-05-02 · How we verify

NCT00002787

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation

Completed Phase 1 Last updated 2 May 2019

What this trial tests

Phase 1 trial testing autologous immunoglobulin idiotype-KLH conjugate vaccine in Refractory Multiple Myeloma in 22 participants. Completed.

Timeline

1 March 1996

Primary endpoint
1 December 2002

Quick facts

Lead sponsor	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	1 March 1996
Primary completion	1 December 2002
Sites	1 location across United States

Drugs / interventions tested

autologous immunoglobulin idiotype-KLH conjugate vaccine — full drug profile →
sargramostim (SARGRAMOSTIM) — full drug profile →
aldesleukin (ALDESLEUKIN) — full drug profile →
laboratory biomarker analysis — full drug profile →

Conditions studied

Refractory Multiple Myeloma — all drugs for Refractory Multiple Myeloma →
Stage I Multiple Myeloma — all drugs for Stage I Multiple Myeloma →
Stage II Multiple Myeloma — all drugs for Stage II Multiple Myeloma →
Stage III Multiple Myeloma — all drugs for Stage III Multiple Myeloma →

Sponsor

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Who can join

Eligibility, any sex, with Refractory Multiple Myeloma or Stage I Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Toxicities graded using the National Cancer Institute (NCI) Common Toxicity Criteria
Time frame: Up to 2 years
Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters for each cohort.
Immune response
Time frame: Up to 2 years
Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters for each cohort.

Sponsor's own description

The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of autologous immunoglobulin idiotype-KLH conjugate vaccine

Trials testing the same drug.

NCT00621036 — Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma · Phase 2 · withdrawn

Other recruiting trials for Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT07181941 — Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refrac · Phase 1, PHASE2 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07093554 — Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patie · Phase 1 · recruiting
NCT07045727 — Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Olde · NA · recruiting
NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002787 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Last refreshed: 2 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing